Biogen elevated Maria C. Freire to board chair.

Chair changes rarely move stocks — but in biotech, they shape risk posture, pipeline patience, and M&A appetite.

The signal shows up later in capital allocation.

What’s the first behavioral shift you’d look for?

#Biogen #InvestorLens

Kroger ended its CEO search by hiring Greg Foran, and the stock popped.

In grocery, thin margins expose weak execution fast. An external CEO usually signals the board wants tighter discipline and accountability.

Now it’s simple: does store-level performance improve?

#Kroger #Retail #InvestorLens

A turnaround restores value. Sustaining it takes leadership.
Starbucks rebounded—but overreliance on growth, not innovation, slowed it again.
Recovery shows discipline. Endurance shows adaptability.

🔗 hbr.org/2008/07/how-...

#ExecutionEdge #InvestorLens

The toughest loss wasn’t financial—it was leadership.

A CEO chasing optics over outcomes hid cracks that numbers couldn’t. 18 months later, collapse.

Numbers hide intent. Leadership exposes it.
🔗 bit.ly/FCLT-Short-T...
#LeadershipAlpha #LongTermThinking #InvestorLens

Markets and models matter—but leadership moves the needle.
94% of GPs say it drives >50% of returns, yet few measure it.

We treat leadership due diligence as alpha generation, not HR.
🔗 bit.ly/Teneo%E2%80%...
#LeadershipAlpha #InvestorLens